Novel mechanistic insights into oxytocin receptor signalling in breast cancer

2021 ◽  
Author(s):  
◽  
Huiping Liu
Keyword(s):  
Breast Cancer ◽  
Oxytocin Receptor ◽  
Receptor Signalling

scholarly journals Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss

2013 ◽  
Vol 26 (9) ◽  
pp. 1161-1171 ◽  
Author(s):  
Lisa Braun ◽  
Friederike Mietzsch ◽  
Petra Seibold ◽  
Andreas Schneeweiss ◽  
Peter Schirmacher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Receptor Signalling ◽  
Prognostic Relevance

scholarly journals The oxytocin receptor signalling system and breast cancer: a critical review

Oncogene ◽  
2020 ◽  
Vol 39 (37) ◽  
pp. 5917-5932 ◽  
Author(s):  
Huiping Liu ◽  
Christian W. Gruber ◽  
Paul F. Alewood ◽  
Andreas Möller ◽  
Markus Muttenthaler
Keyword(s):  
Breast Cancer ◽  
Current Knowledge ◽  
Oxytocin Receptor ◽  
Cancer Development ◽  
Breast Cancer Cell Lines ◽  
Maternal Behaviour ◽  
Supporting Evidence ◽  
Breast Cancer Development ◽  
Signalling System ◽  
Cancer Management

Abstract Breast cancer is making up one-quarter of all new female cancer cases diagnosed worldwide. Breast cancer surgeries, radiation therapies, cytotoxic chemotherapies and targeted therapies have made significant progress and play a dominant role in breast cancer patient management. However, many challenges remain, including resistance to systemic therapies, tumour recurrence and metastasis. The cyclic neuropeptide oxytocin (OT) elicits a plethora of biological responses via the oxytocin receptor (OTR) in both the central and peripheral nervous system, including social bonding, stress, maternal behaviour, sexual activity, uterus contraction, milk ejection and cancer. As a typical member of the G protein-coupled receptor family, OTR represents also an intriguing target for cancer therapy. There is emerging evidence that OTR plays a role in breast cancer development and progression, and several breast cancer cell lines express OTR. However, despite supporting evidence that OT lowers breast cancer risks, its mechanistic role in breast cancer development and the related signalling pathways are not fully understood. Here, we review the current knowledge of the OT/OTR signalling system in healthy breast tissue as well as in breast cancer, and discuss OTR as a potential therapeutic target for breast cancer management.

Anti-lactadherin antibodies in anti-angiogenic cancer therapy of breast cancer stem cells

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14138-14138 ◽  
Author(s):  
A. A. Epenetos ◽  
G. Bower ◽  
M. Deonarain ◽  
L. Bonney
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Human Breast Cancer ◽  
Tumor Vasculature ◽  
Breast Cancer Cell Lines ◽  
Human Breast ◽  
Integrin Receptor ◽  
Receptor Signalling

14138 Background: Angiolix (Hu-Mc3) is a humanized monoclonal antibody that recognizes a migrating adhesion molecule called Lactadherin. This novel antibody has a high affinity for its antigen and recognizes an epitope on Lactadherin which interacts with the the ’RGD’- motif found on integrin receptors on newly formed endothelial cells. Lactadherin binding leads to signalling via a VEGF-independent integrin receptor signalling cascade leading to vascular endothelial cell profileration. Lactadherin binding may also increase the potency of VEGF-VEGF receptor signalling. Methods: We studied the expression of Lactadherin on breast cancer cell lines, the biodistribution of Angiolix in human breast cancer xeografts and its ability to inhibit tumor growth in vivo. Results: Our data show that tumor cells express lactadherin in vivo and that Angiolix could achieve more than 75% growth inhibition of human breast cancer growing as xenografts . Conclusions: In view of the recent finding that cancer stem cells can over-express the pro-angiogenic VEGF and make a major contribution to tumor vasculature proliferation leads to the possibility that Angiolix may be able to act to specifically target breast cancer stem cell and cause tumor regression by blocking the growth of tumor vasculature by its ability to neutralise Lactadherin-integrin receptor binding. [Table: see text]

scholarly journals Differential expression of the oxytocin receptor, OXTR, in cancers of the breast.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Oxytocin Receptor ◽  
Normal Breast ◽  
Breast Cancer Patients ◽  
Gene Encoding ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Tumor Expression ◽  
Microarray Datasets

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2 , 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding the oxytocin receptor, OXTR, when comparing primary tumors of the breast to the tissue of origin, the normal breast. OXTR expression in primary tumors of the breast was significantly lower than in normal breast tissue, and relapse-free survival in breast cancer patients was significantly longer in patients with high tumor expression of OXTR than in patients with low tumor expression of OXTR. OXTR may be of relevance to initiation, maintenance or progression of cancers of the female breast.

Sign in / Sign up

Export Citation Format

Share Document